Shares of Glenmark Pharmaceuticals Ltd remain in focus following a $1.925 billion (around ₹19,000 crore) licensing agreement between its innovation arm, IGI, and global biopharmaceutical company AbbVie.
The deal, centred on ISB 2001, is seen as a validation of Glenmark’s research capabilities and could provide long-term revenue opportunities through milestone payments and royalties.
With a market capitalisation of ₹60,870 crore, Glenmark shares closed at ₹2,156, up 0.95% from the previous session. The stock has gained around 30% over the past year.
Investec retains Buy rating
Investec has maintained its Buy rating on the stock and raised its target price to ₹2,750, implying an upside of around 27.5% from the closing price.
The brokerage expects strong earnings visibility through FY30.
Management guides for higher growth
Glenmark has guided for:
- Sales growth of 13-15% through FY30.
- Margin expansion of around 100 basis points.
Management expects growth to be driven by:
- The branded pharmaceutical business.
- Increasing contribution from innovation-led products.
India business remains a key growth driver
The company expects the domestic business to grow by more than 15%.
Growth is likely to be supported by:
- New product launches.
- Expansion of the GLP-1 portfolio.
- Higher focus on oncology.
- Addition of medical representatives.
US and international markets add support
Management expects the US business to benefit from:
- Growth in respiratory products.
- Expansion of injectable products.
- Integration benefits from Monroe.
- First-to-File launch opportunities.
The Rest of World (RoW) business continues to provide steady growth and remains another support for revenues.
AbbVie deal validates innovation platform
IGI signed a licensing agreement worth $1.925 billion with AbbVie for ISB 2001.
According to the company, the agreement highlights the potential of its proprietary BEAT platform in oncology and autoimmune diseases.
Key features of the deal
- Upfront payment of $700 million.
- Milestone-based payments.
- Future royalty opportunities.
Management believes the transaction could diversify Glenmark’s revenue mix and create a new long-term growth engine.
Scope for more partnerships
The company said the deal strengthens the global credibility of its innovation pipeline.
Management plans to file at least:
- One Investigational New Drug (IND) application every year from FY27.
It also remains open to additional strategic partnerships and licensing agreements.
Strong quarterly performance
For Q4FY26, Glenmark reported:
- Revenue from operations of ₹3,771 crore, up 16% from ₹3,256 crore a year earlier.
- EBITDA of ₹763 crore, compared with ₹561 crore in Q4FY25.
- EBITDA growth of 36%.
- Net profit of ₹301 crore, up 52% from ₹198 crore in the corresponding quarter.
- Earnings per share of ₹10.68, compared with ₹0.16 a year ago.
About the company
Founded in 1977, Glenmark Pharmaceuticals is a Mumbai-based pharmaceutical company with a presence in branded generics, specialty medicines and over-the-counter products.
Its key therapeutic segments include:
- Dermatology.
- Respiratory.
- Oncology.
Key numbers at a glance
| Particulars | Details |
|---|---|
| Market capitalisation | ₹60,870 crore |
| Closing share price | ₹2,156 |
| Investec target price | ₹2,750 |
| Implied upside | 27.5% |
| AbbVie deal value | ₹19,000 crore |
| Upfront payment | $700 million |
| FY30 sales growth guidance | 13-15% |
| India business growth guidance | Above 15% |
Outlook
The AbbVie transaction marks an important step in Glenmark’s efforts to build an innovation-led business alongside its traditional generics operations.
Management expects the deal, combined with growth in India and the US, to strengthen earnings visibility and create additional long-term opportunities.
TL;DR
Glenmark’s ₹19,000 crore licensing agreement with AbbVie provides upfront payments, milestone-linked earnings and royalty opportunities. Investec has retained a Buy rating with a target price of ₹2,750, citing strong growth visibility through FY30.
AI Summary
- Glenmark’s innovation arm signed a $1.925 billion deal with AbbVie.
- The agreement includes a $700 million upfront payment.
- Investec maintained a Buy rating and a ₹2,750 target price.
- Management has guided for 13-15% sales growth through FY30.
- The company plans to file at least one IND application every year from FY27.
